← Back to Search

BTK Inhibitor

Acalabrutinib for Diffuse Large B-Cell Lymphoma

Phase 1
Waitlist Available
Research Sponsored by Acerta Pharma BV
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Relapsed or refractory disease
Pathologically confirmed de novo ABC DLBCL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment to the date of disease progression, assessed up to cycle 48 (1 cycle is 28 days)
Awards & highlights

Study Summary

This trial looked at the safety of a new drug, acalabrutinib, in people with a certain type of lymphoma that has come back or does not respond to treatment.

Who is the study for?
This trial is for adults over 18 with a specific type of lymphoma called de novo ABC DLBCL that has come back or hasn't responded to treatment. They must have at least one measurable site of the disease. It's not for those with serious heart issues, pregnant or breastfeeding women, anyone with life-threatening conditions, gastrointestinal disorders, or bowel obstruction.Check my eligibility
What is being tested?
The trial is testing Acalabrutinib's safety in patients who have relapsed or are refractory to other treatments for the ABC subtype of Diffuse Large B-Cell Lymphoma (DLBCL).See study design
What are the potential side effects?
While not explicitly listed here, common side effects from drugs like Acalabrutinib may include headaches, diarrhea, muscle and joint pain, reduced blood cell counts leading to increased infection risk and bleeding problems.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My condition has returned or didn't respond to treatment.
Select...
My cancer is a type of aggressive lymphoma diagnosed for the first time.
Select...
I have at least one tumor that can be measured.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment to the date of disease progression, assessed up to cycle 48 (1 cycle is 28 days)
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment to the date of disease progression, assessed up to cycle 48 (1 cycle is 28 days) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Safety Profile of Acalabrutinib in Subjects With Relapsed or Refractory ABC DLBCL.
Secondary outcome measures
Area Under the Plasma Concentration (AUC)
Evaluate Activity of Acalabrutinib as Measured by Overall Response Rate (ORR)
Evaluate Pharmacodynamic (PD) Effects (Done at US Sites Only)
+1 more

Side effects data

From 2020 Phase 2 trial • 177 Patients • NCT04346199
2%
Headache
1%
Chronic obstructive pulmonary disease
1%
Septic shock
1%
Ischaemic stroke
100%
80%
60%
40%
20%
0%
Study treatment Arm
BSC Alone
Acalabrutinib + BSC

Trial Design

1Treatment groups
Experimental Treatment
Group I: AcalabrutinibExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acalabrutinib
2020
Completed Phase 2
~2050

Find a Location

Who is running the clinical trial?

Acerta Pharma BVLead Sponsor
45 Previous Clinical Trials
5,904 Total Patients Enrolled
AstraZeneca Clinical TrialsStudy Director1-877-240-9479; information.center@astrazeneca.com

Media Library

Acalabrutinib (BTK Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT02112526 — Phase 1
Diffuse Large B-Cell Lymphoma Research Study Groups: Acalabrutinib
Diffuse Large B-Cell Lymphoma Clinical Trial 2023: Acalabrutinib Highlights & Side Effects. Trial Name: NCT02112526 — Phase 1
Acalabrutinib (BTK Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02112526 — Phase 1
~2 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top